ArticleCell death discovery2026
Histone lactylation modification promotes docetaxel resistance and tumor progression through CNN1-Mediated autophagy and cell cycle arrest in Castration-resistant prostate cancer.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lactylation Remodels Tumorigenesis, Immune Microenvironment, and Therapeutic Response.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Castration-resistant prostate cancer (CRPC) constitutes an advanced stage of prostate cancer (PCa) that emerges following conventional androgen deprivation therapy (ADT). Docetaxel (DTX), a standard chemotherapeutic agent, is integral to the therapeutic regimen for CRPC. However, the development of resistance to DTX has significantly impeded its clinical efficacy. Histone lactylation and elevated lactate production are emerging as critical factors in cancer biology, yet their roles in CRPC and DTX resistance remain poorly understood. This study investigated the relationship between histone lactylation, lactate production, and DTX resistance in CRPC. Clinical analysis revealed significantly increased pan-lactylated protein (Pan Kla) expression in CRPC tissues compared to PCa, accompanied by elevated lactate production and lactate dehydrogenase (LDH) activity. Higher Pan Kla expression was linked to poor prognosis in CRPC. DTX-resistant CRPC (CRPC-R) samples exhibited significantly elevated Pan Kla and histone lactylation modifications, especially at H3K18la and H4K12la sites. Inhibition of lactate production using 2-deoxyglucose (2-DG) and oxamate reduced DTX resistance, suppressed cell migration, induced G0/G1 phase arrest, and promoted autophagy. Moreover, CNN1 was identified as a potential downstream target of histone lactylation modifications in CRPC. Elevated CNN1 expression correlated with increased lactylation and DTX resistance, whereas its inhibition reversed the effects of lactate inhibition on cell cycle progression and autophagy. In vivo, CNN1 overexpression counteracted the tumor-suppressive effects of lactate inhibition, restoring tumor growth and autophagy levels. These findings suggested that histone lactylation and lactate metabolism, mediated by CNN1, play a crucial role in DTX resistance and tumor progression in CRPC, offering potential therapeutic targets for overcoming chemoresistance in CRPC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.